Inhibikase Therapeutics Inc. logo

Inhibikase Therapeutics Inc.

IKT | NASDAQ
Chart Builder DCF Calculator
$2.31
+$0.11 (+5.00%)
At close: Sep 22, 2026, 4:00 PM ET
$2.31
$0 (0.00%)
After-hours: Sep 22, 2026, 7:30 PM ET

Market Data

Market Cap
$290.47M
Enterprise Value
$131.45M
Beta
0.96
Average Volume
739.95K
Shares Outstanding (Diluted)
174.57M
Shares Change YoY
93.95%
Institutional Ownership
66.16%
Exchange
NASDAQ
ISIN
US45719W2052

Price Performance

Price Change 1M
-8.7%
Price Change 3M
17.6%
Price Change 6M
35.0%
Price Change YTD
12.8%
Price Change 1Y
30.9%
Price Change 3Y
76.0%
Price Change 5Y
-81.9%
1M CAGR (ann.)
-10.9%
1Y CAGR (ann.)
42.9%
5Y CAGR (ann.)
-30.2%
All-Time CAGR
-43.6%

Valuation

PE Ratio
-4.58
Forward PE
N/A
PEG Ratio
-0.04
Forward PEG
-0.75
PS Ratio
N/A
Forward PS
580.90
PB Ratio
1.89
P/FCF Ratio
-6.75
P/Adj. FCF Ratio
-4.61
P/OCF Ratio
-9.17
EV/Sales
N/A
EV/EBIT
-2.11
EV/EBITDA
-2.11
EV/FCF
-3.05
Earnings Yield
-21.8%
FCF Yield
-14.8%
Adj. FCF Yield
-21.7%

Financial Health

Net Cash
$159.02M
Total Debt
$0
Cash & Short-Term Investments
$159.02M
Total Assets
$163.59M
Current Ratio
15.82
Quick Ratio
15.82
Debt / Equity Ratio
0.00
Debt / EBITDA
-0.00
Debt / FCF
-0.00
OCF / Debt
N/A
Interest Coverage
0.00
Altman Z-Score
15.32
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
0.0%
Operating Profit Margin
0.0%
EBITDA Margin
0.0%
Net Profit Margin
0.0%
FCF Margin
N/A
Adj. FCF Margin
N/A
SBC / Revenue
0.0%
SBC Impact (per share)
-46.4%

Returns

Return on Assets
-37.1%
Return on Equity
-42.8%
Return on Invested Capital
-42.9%
Return on Capital Employed
-42.9%
Return on Tangible Assets
-37.1%

Historical Growth (CAGR)

Revenue CAGR 3Y
-150.0%
Revenue CAGR 5Y
-71.2%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
72.6%
EPS CAGR 5Y
38.3%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-50.2%
FCF CAGR 5Y
-25.2%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Hold
Analyst Count
2
EPS Growth Next 3Y
18.1%
Revenue Growth Next 3Y
N/A
Earnings Date
Nov 12, 2026
EPS Estimate (next Q)
-$0.11
EPS Growth Est (next Q)
-15.4%
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$6.50
Price Target Upside
195.5%

Cash Flow

Operating Cash Flow
$-42.61M
Free Cash Flow
$-43.06M
Adj. Free Cash Flow
$-63.03M
FCF Per Share
-$0.25
OCF Per Share
-$0.24
OCF/S Ratio
0.0%

Income Statement

Revenue
$0
Gross Profit
$0
Operating Income
$-65.81M
EBITDA
$-62.34M
Net Income
$-60.64M
EPS (Diluted)
-$0.48
Revenue / Employee
N/A
Profit / Employee
$-1.73M
Employees
35

© 2026 bestshares.com. All rights reserved.